Abstract :
[en] With 5-year survival rates below 5%, small cell lung carcinoma (SCLC) has very poor prognosis and requires improved therapies. Despite an excellent overall response to first-line therapy, relapses are frequent and further treatments are disappointing. The goal of the study was to improve secondline therapy of SCLC.
The effect of chemotherapeutic agents was evaluated in cell lines (apoptosis, reactive oxygen species, and RNA and protein expression) and in mouse models (tumour development).
We demonstrate here that valproic acid, a histone deacetylase inhibitor, improves the efficacy of a second-line regimen (vindesine, doxorubicin and cyclophosphamide) in SCLC cells and in mouse models.
Transcriptomic profiling integrating microRNA and mRNA data identifies key signalling pathways in the response of SCLC cells to valproic acid, opening new prospects for improved therapies.
Name of the research project :
The Interuniversity Attraction Poles programme BELVIR initiated by the Belgian Science Policy Office
The Action de Recherche Concertée Glyvir of the Communauté française de Belgique
Synbiofor
Agricultureislife
The Plan Cancer of the Service Public Fédéral
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Télévie [BE]
BELSPO - Belgian Science Policy Office [BE]
CFB - Communauté française de Belgique [BE]
Belgian Foundation Against Cancer [BE]
NEDO - New Energy and Industrial Technology Development Organization [JP]
SPW DGO6 - Service Public de Wallonie. Economie, Emploi, Recherche [BE]
CAC - Centre anticancéreux près l'Université de Liège asbl [BE]
ULiège. GxABT - Liège Université. Gembloux Agro-Bio Tech [BE]
ULg FSR - Université de Liège. Fonds spéciaux pour la recherche [BE]
Scopus citations®
without self-citations
9